Pilot Study of Low-Dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: … (Abstract)

Pilot Study of Low-Dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-Controlled, Crossover Clinical Trial Clin Ther 10 April 2023 https://pubmed.ncbi.nlm.nih.gov/37045708/ Purpose: Low-dose naltrexone (LDN) is commonly used to control pain and other symptoms, especially in patients with autoimmune diseases, but with limited evidence. This study tests the efficacy […]

‘Promising Results’ for Low-Dose Naltrexone as Pain Reliever (News)

‘Promising Results’ for Low-Dose Naltrexone as Pain Reliever Pain News Network 15 November 2022 https://www.painnewsnetwork.org/stories/2022/11/15/promising-results-for-low-dose-naltrexone-as-pain-reliever Low-dose naltrexone (LDN) continues to get more recognition from the medical community as a treatment for some types of chronic pain. In smaller doses of 5mg or less, patients with fibromyalgia, interstitial cystitis, intractable pain and other chronic conditions have […]

Low-Dose Naltrexone Promising for pain relief in fibromyalgia and host of chronic conditions (News)

Low-Dose Naltrexone Promising for pain relief in fibromyalgia and host of chronic conditions Medical Dialogues 15 November 2022 https://medicaldialogues.in/medicine/news/low-dose-naltrexone-promising-for-pain-relief-in-fibromyalgia-and-host-of-chronic-conditions-102374 A new study found that low dose naltrexone (LDN) helped with chronic pain stemming from various conditions including fibromyalgia, Crohn’s disease, diabetic neuropathy, axial low back pain, rheumatoid arthritis, and complex regional pain syndrome. A review […]

Tracey – US: Hashimoto’s, RA (LDN; low dose naltrexone)

  Linda Elsegood: Welcome to the LDN radio show brought to you by the LDN Research Trust I’m your host, Linda Elsegood. I have an exciting lineup of guest speakers who are LDN experts in their field. We will be discussing low-dose naltrexone and its many uses in autoimmune diseases, cancers, etc. Thank you for […]